Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of 9-ING-41 Plus Carboplatin in Advanced Salivary Gland Carcinoma
NCT05010629Phase 2Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elraglusib in salivary gland carcinoma (SGC). Started Sep 2021; status: active, not recruiting.
02
Drugs
elraglusib
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT05010629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010629.